Sinopharm COVID-19 vaccine-induced Stevens–Johnson syndrome

Boualila, Lina; Mrini, Basma; Tagmouti, Adam; Moubarik, Najoua El; Belabbes, Meryem Benchekroun; Boutimzine, Nouredine; Cherkaoui, Lalla Ouafa

doi:10.1016/j.jfo.2021.12.005

Cited by 7 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 11 , 13 The inactive components of COVID‐19 vaccines, or excipients, might also contribute to triggering the type IV hypersensitivity reaction mediating TEN/SJS. 14 , 15 Finally, it is hypothesized that the mucosal damage seen in post‐vaccination TEN/SJS is mediated by the host's production of neutralizing antibodies against the SARS‐CoV‐2 spike protein. 16 …”

Section: Discussionmentioning

confidence: 99%

“…11,13 The inactive components of COVID-19 vaccines, or excipients, might also contribute to triggering the type IV hypersensitivity reaction mediating TEN/SJS. 14,15 Finally, it is hypothesized that the mucosal damage seen in post-vaccination TEN/SJS is mediated by the host's production of neutralizing antibodies against the SARS-CoV-2 spike protein. 16 Regarding TEN/SJS after COVID-19 infection, it is hypothesized that the generalized immune activation and the associated increase in cytokines induced by COVID-19 infection can directly trigger or make individuals more susceptible to TEN/SJS-inducing type IV hypersensitivity reactions.…”

Section: Discussionmentioning

confidence: 99%

“…However, others contend that the pathophysiology of post‐COVID‐19 vaccine TEN/SJS lies in the activation of type 1 helper T‐cells (Th1s), which released cytokines such as TNF‐ɑ and IFN‐ɣ that subsequently activate cytotoxic CD8+ T‐cells responsible for triggering keratinocyte apoptosis 11,13 . The inactive components of COVID‐19 vaccines, or excipients, might also contribute to triggering the type IV hypersensitivity reaction mediating TEN/SJS 14,15 . Finally, it is hypothesized that the mucosal damage seen in post‐vaccination TEN/SJS is mediated by the host's production of neutralizing antibodies against the SARS‐CoV‐2 spike protein 16 …”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Toxic epidermal necrolysis and Stevens‐Johnson syndrome after COVID‐19 infection and vaccination

Zou

Daveluy

2022

Aust J Dermatology

View full text Add to dashboard Cite

Stevens‐Johnson Syndrome (SJS) is a rare but severe skin reaction characterized by blistering and peeling of the skin and ulcerations of mucous membranes; toxic epidermal necrolysis (TEN) is a subset of SJS characterized by the involvement of >30% of the skin. Though previously associated with drugs and infections, discussions on the association between TEN/SJS and COVID‐19 have been limited. We present a review of TEN/SJS after COVID‐19 infection and vaccination. Literature searches were conducted on PubMed and Google Scholar from 2019 to 8/2022. Thirty‐eight articles were selected based on subject relevance, and references within selected articles were also screened for relevance. As of 8/2022, there have been 34 published cases of TEN, SJS, and SJS‐TEN overlap after COVID‐19 infection and vaccination, including 12 cases after vaccination and 22 cases after infection. Multiple authors hypothesize that virotopes or excipients in COVID‐19 vaccines can activate T‐cells or cytokines to induce TEN/SJS. Meanwhile, some hypothesize that COVID‐19 infection induces immune activation that can trigger TEN/SJS or increase susceptibility to drug‐induced TEN/SJS. Treatments for post‐infection and post‐vaccination TEN/SJS vary significantly. We recommend remaining vigilant for this rare and severe potential complication.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Toxic epidermal necrolysis and Stevens‐Johnson syndrome after COVID‐19 infection and vaccination

Zou

Daveluy

2022

Aust J Dermatology

View full text Add to dashboard Cite

show abstract

“…The distinction of between SJS and TEN is clinically based on the involved total body surface area: SJS is <10% and TEN is >30% [102] . Zou and Daveluy [103] collected 12 cases with TEN/SJS after COVID-19 vaccinations [83,102,[104][105][106][107][108][109][110][111][112][113] along with 22 cases with TEN/SJS after COVID-19 infection, which had been reported until August 2022. Seven additional case reports (7 patients) of vaccine-related SJS/TEN were found at the time of manuscript writing in Oct 2023 [114][115][116][117][118][119][120] .…”

Section: Iii) Erythema Multiforme Typementioning

confidence: 99%

The pathophysiology and clinical phenotypes of COVID-19 mRNA vaccine-related cutaneous adverse reactions: A narrative review

Ishikawa

2024

Trends Immunother.

View full text Add to dashboard Cite

Cutaneous adverse reactions (CARs) after COVD-19 messenger ribonucleic acid (mRNA) vaccines have been reported worldwide, but the pathophysiology of CARs remains to be elucidated. To understand the pathophysiology, it is essential to know how the innate and adaptive immunity are activated after vaccination. At present, majority of CARs are presumed to be evoked by innate immunity response. Reviewing the previous articles, I propose the clinical classification of CARs; local injection site reaction, generalized eruption, localized eruption and others. Since COVID-19 mutates continuously to overcome the existing vaccines, our steady efforts are indispensable to clarify the pathophysiology of CARs and contribute to the development of novel vaccines with least adverse events and high efficacy.

show abstract

“…2,5 In a systematic review including 229 studies, 4 cases (0.07%) were reported after the COVID-19 vaccine. 6 Besides this review, new cases were reported further [7][8][9][10] (Table 1). In our case, there was no history of new medication in the last 2 months; so the current picture was attributed to the COVID-19 vaccine.…”

mentioning

confidence: 99%

Stevens–Johnson syndrome/toxic epidermal necrolysis overlap case possibly induced by COVID‐19 vaccine

Cenk

Karataş

Çetin

et al. 2023

Acad Dermatol Venereol

View full text Add to dashboard Cite

Sinopharm COVID-19 vaccine-induced Stevens–Johnson syndrome

Cited by 7 publications

References 22 publications

Toxic epidermal necrolysis and Stevens‐Johnson syndrome after COVID‐19 infection and vaccination

Toxic epidermal necrolysis and Stevens‐Johnson syndrome after COVID‐19 infection and vaccination

The pathophysiology and clinical phenotypes of COVID-19 mRNA vaccine-related cutaneous adverse reactions: A narrative review

Stevens–Johnson syndrome/toxic epidermal necrolysis overlap case possibly induced by COVID‐19 vaccine

Contact Info

Product

Resources

About